Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Topical Cream 1.5% in Atopic Dermatitis
NCT06673654Phase 1Completed
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruxolitinib cream in atopic dermatitis (AD) (3 arms). Primary endpoints: Therapeutic Equivalence at 8 weeks, Superiority at 8 weeks and 1 more. Started Aug 2023; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06673654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673654.